Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin-Reference-Cited by-同舟云学术

Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin

Published:2024-08-07 Issue:1 Volume:14 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Senapati Jayastu^ORCID,Jabbour Elias^ORCID,Short Nicholas J.^ORCID,Jain Nitin,Haddad Fadi^ORCID,Bathala Tharakeswara,Kovalenko Iuliia^ORCID,Bidikian Aram,Ravandi Farhad^ORCID,Khouri Issa,Kadia Tapan M.^ORCID,Garris Rebecca,Montalban Bravo Guillermo,Chien Kelly,Shpall Elizabeth,Kebriaei Partow,Kantarjian Hagop M.^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41408-024-01098-4.pdf

Reference20 articles.

1. Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, et al. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023;16:22.

2. Senapati J, Kantarjian H, Haddad FG, Short NJ, Welch MA, Jain N, et al. SOHO state of the art updates and next questions next questions: acute lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024;24:333–9.

3. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl J Med. 2016;375:740–53.

4. Short NJ, Jabbour E, Jain N, Kantarjian H. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions. J Hematol Oncol. 2024;17:32.

5. Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125:2474–87.